Company Name
Drug
Event
Outcome
Details
Biohaven Pharmaceutical Holding Co Ltd.
(BHVN)
Zavegepant nasal spray (NDA)
Q1 2023
FDA decision on Zavegepant nasal spray for the acute treatment of migraine in adults.
Pending-
MediWound Ltd.
(MDWD)
NexoBrid (Resubmitted BLA)
01/01/2023
FDA decision on NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns
FDA approved NexoBrid for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns on Dec.29, 2022-
Vericel Corporation
(VCEL)
NexoBrid (Resubmitted BLA)
01/01/2023
FDA decision on NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns
FDA approved NexoBrid for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns on Dec.29, 2022-
Read More Get Access to Premium FDA Calendar with RTT Biotech Investor.